PMID- 35567293
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 23
DP  - 2022 May 14
TI  - Case Series of Successful Intravenous Immunoglobulin (IVIG) Treatment in 4 
      Pregnant Patients with Severe COVID-19-Induced Hypoxia.
PG  - e936734
LID - 10.12659/AJCR.936734 [doi]
AB  - BACKGROUND Despite unprecedented speed in the execution of the COVID-19 vaccine 
      and therapeutic clinical trials, pregnant patients have been largely excluded 
      from initial studies. In addition, pregnant patients who are unvaccinated against 
      SARS-CoV-2 have greater morbidity risk with severe COVID-19 disease as compared 
      to patients of similar age and comorbidity status. Intravenous immunoglobulin 
      (IVIG) has been deemed safe in pregnancy in other diseases. Prior data 
      demonstrate the possible benefit of utilizing IVIG for the treatment in 
      hospitalized patients with severe respiratory symptoms associated with COVID-19 
      active infections when administered within 14 days of COVID symptom onset. CASE 
      REPORT We administered IVIG (Privigen(R), CSL Behring) 0.5 g/kg daily for 3 
      consecutive days to 4 pregnant patients (ages 24-34 years of age) who were 
      hospitalized with moderate-to-severe COVID-19 and not vaccinated against 
      SARS-CoV-2. All patients received concomitant glucocorticoid therapy. Gestational 
      ages were 26, 17, 35, and 35 weeks. All patients were discharged home breathing 
      room air after a mean hospital stay of 15 days. Two patients had uncomplicated 
      cesarean section at 35 weeks during the hospitalization. The pre-term pregnancies 
      at 17 and 26 weeks were intact at hospital discharge and resulted in normal 
      vaginal deliveries at term. All 4 patients consented to participate in this case 
      series report. CONCLUSIONS IVIG may be a safe treatment consideration in pregnant 
      women with severe COVID-19 to avoid pregnancy complications. Its use warrants 
      further study in pregnancy acute respiratory distress syndrome (ARDS) due to 
      SARS-CoV-2, influenza, and other respiratory viruses to which pregnant patients 
      are vulnerable.
FAU - Geriak, Matthew
AU  - Geriak M
AD  - Department of Research, Sharp Healthcare, San Diego, CA, USA.
FAU - McGrosso, Dominic
AU  - McGrosso D
AD  - Department of Pharmacology, University of California at San Diego, La Jolla, CA, 
      USA.
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California 
      at San Diego, La Jolla, CA, USA.
FAU - Gonzalez, David J
AU  - Gonzalez DJ
AD  - Department of Pharmacology, University of California at San Diego, La Jolla, CA, 
      USA.
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California 
      at San Diego, La Jolla, CA, USA.
FAU - Dehner, Matthew
AU  - Dehner M
AD  - Department of Pharmacy, Sharp Memorial Hospital, San Diego, CA, USA.
FAU - Sakoulas, George
AU  - Sakoulas G
AD  - Department of Research, Sharp Healthcare, San Diego, CA, USA.
AD  - Department of Infectious Diseases, Sharp Rees-Stealy Medical Group, San Diego, 
      CA, USA.
AD  - Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of 
      Pediatrics, University of California at San Diego School of Medicine, La Jolla, 
      CA, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220514
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - COVID-19 Vaccines
MH  - Cesarean Section
MH  - Female
MH  - Humans
MH  - Hypoxia/etiology
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Pregnancy
MH  - SARS-CoV-2
MH  - Young Adult
PMC - PMC9115731
COIS- Conflict of interest: Matthew Geriak, Dominic McGrosso, David J. Gonzalez, 
      Matthew Dehner: Nothing to disclose. George Sakoulas: Received speaking honoraria 
      from Allergan, Sunovion and consulting fees from Allergan and Paratek 
      Pharmaceuticals
EDAT- 2022/05/15 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/05/14
CRDT- 2022/05/14 01:32
PHST- 2022/05/14 01:32 [entrez]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/05/14 00:00 [pmc-release]
AID - 936734 [pii]
AID - 10.12659/AJCR.936734 [doi]
PST - epublish
SO  - Am J Case Rep. 2022 May 14;23:e936734. doi: 10.12659/AJCR.936734.